Dr. Surendra Varma Appointed to Texas Medical Board District Three Review Committee

Translate to Spanish or other 102 languages!

Governor Greg Abbott has appointed Surendra Varma, M.D. to the Texas Medical Board (TMB) District Three Review Committee for a term set to expire on January 15, 2026. Image source: Facebook
Governor Greg Abbott has appointed Surendra Varma, M.D. to the Texas Medical Board (TMB) District Three Review Committee for a term set to expire on January 15, 2026. Image source: Facebook
- Advertisement -

AUSTIN – Governor Greg Abbott has appointed Surendra Varma, M.D. to the Texas Medical Board (TMB) District Three Review Committee for a term set to expire on January 15, 2026.

Surendra Varma, M.D. of Lubbock is the executive associate dean for graduate medical education at the Texas Tech University Health Sciences Center (TTUHSC) and is a Grover E. Murray Professor and Ted Hartman Endowed Chair in Medical Education at TTUHSC. He is an associate editor for Advances in Pediatrics, editorial board member for the Journal of Clinical Endocrinology and Metabolism, and a member of the American Pediatric Society, Society for Pediatric Research, Endocrine Society, and the Council on Graduate Medical Education for the Health Resources & Services Administration. He is a member and former president of the American Diabetes Association and a member and former Texas affiliate chair of endocrinology for the American Academy of Pediatrics. Previously, he served as a gubernatorial appointee on the TMB District Three Review Committee for six years, TMB for five years, and the Task Force on Infectious Disease Preparedness and Response for four years. Varma received a Bachelor of Science in Physics, Chemistry, Biology and English from the University of Lucknow, and a Bachelor of Medicine, a Bachelor of Surgery, and a Doctor of Medicine in Pediatrics from King George Medical University (KGMU). He has received honorary Doctorate (DSc) from KGMU and Honorary Fellowship (FRCP) from Royal College of Physicians. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease.

FDA Authorizes First Wearable Device that Continuously Monitors Both Ketone Levels and Blood Sugar

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.
- Advertisement -